Chromogenic Anti-FXa Assay Calibrated With Low Molecular Weight Heparin in Patients Treated With Rivaroxaban and Apixaban: Possibilities and Limitations

Biochemia Medica - Croatia
doi 10.11613/bm.2020.010702
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Croatian Society for Medical Biochemistry and Laboratory Medicine

Related search

Low Molecular Weight Heparin

Reactions Weekly
2014English

Low Molecular Weight Heparin

Journal of Cardiothoracic and Vascular Anesthesia
Cardiovascular MedicineAnesthesiologyPain MedicineCardiology
1992English

Low Molecular Weight Heparin

Reactions Weekly
2013English

Low Molecular Weight Heparin

2020English

Cost-Effectiveness Analysis of Treatment of Venous Thromboembolism With Rivaroxaban Compared With Combined Low Molecular Weight Heparin/Vitamin K Antagonist

Thrombosis Journal
Hematology
2015English

Rivaroxaban Versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Advanced Upper Gastrointestinal Tract and Hepatopancreatobiliary Cancer

In Vivo
BiochemistryMedicineGeneticsPharmacologyMolecular Biology
2020English

Treatment of Lived Vasculopathy With Low-Molecular-Weight Heparin

Archives of Dermatology
2003English

Low Molecular Weight Heparin or Unfractionated Heparin in the Treatment of Patients With Uncomplicated Deep Vein Thrombosis

Emergency Medicine Journal
MedicineCritical CareEmergency MedicineIntensive Care Medicine
2000English

Treatment Refractory Chronic Spontaneous Urticaria Patients Achieves Remission With Low Molecular Weight Heparin

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy